OncosightAI - AI Digital Pathology

⚠️ The Problem

Pathologists face overwhelming caseloads, leading to diagnostic fatigue and potential errors. Manual biomarker quantification is time-consuming and subject to inter-observer variability. Rare cancer cells are easily missed in large tissue samples.

🔍 Missed Diagnoses

Small cancer foci and micrometastases are frequently overlooked in screening

😓 Pathologist Shortage

Growing caseloads with limited pathologists lead to diagnostic delays

📊 Subjective Scoring

Manual biomarker quantification (HER2, PD-L1) shows high variability

⏱️ Time-Consuming

Manual screening of entire slides takes hours, delaying diagnosis

✅ The Solution: OncosightAI

AI-powered digital pathology platform that detects cancer with 98% sensitivity, quantifies biomarkers objectively, and reduces pathologist screening time by 50%.

🔍 Cancer Detection AI

98% sensitivity for cancer detection with 90% fewer missed micrometastases

📊 Biomarker Quantification

Objective, reproducible scoring of HER2, PD-L1, Ki-67, and other biomarkers

⚡ 50% Time Savings

AI pre-screens slides, flagging regions of interest for pathologist review

🎯 Quality Assurance

Second-read AI reduces inter-observer variability and diagnostic errors

🚀 Key Features

🔬 Digital Pathology AI (1 service)

Cancer Detection: Whole slide imaging analysis with 98% sensitivity for cancer

Micrometastasis Detection: Identification of small tumor deposits in lymph nodes (90% fewer missed cases)

Tumor Segmentation: Automatic delineation of tumor vs. normal tissue

Histologic Grading: AI-assisted Gleason scoring (prostate), Nottingham grade (breast), etc.

Multi-Stain Support: H&E, IHC, special stains analysis

🎯 Biomarker Quantification (1 service)

HER2 Scoring: Automated breast cancer HER2 quantification (0, 1+, 2+, 3+)

PD-L1 TPS: Tumor proportion score for immunotherapy eligibility

Ki-67 Index: Proliferation marker quantification for prognosis

ER/PR Scoring: Estrogen/progesterone receptor quantification (% positive cells, intensity)

MSI/MMR: Microsatellite instability and mismatch repair assessment

🧠 How OncosightAI Works

1️⃣ Whole Slide Scanning

High-resolution digitization of glass slides at 40x magnification

2️⃣ AI Analysis

Deep learning models trained on 100,000+ annotated slides

3️⃣ Region Flagging

Suspicious areas highlighted for pathologist attention

4️⃣ Expert Review

Pathologist confirms AI findings and issues final report

💡 Use Cases

🏥 Hospital Pathology Labs

Impact: 50% reduction in pathologist screening time for cancer cases

High-volume cancer screening, lymph node examination, quality assurance

🔬 Reference Laboratories

Impact: 90% fewer missed micrometastases in sentinel lymph nodes

Specialized cancer diagnostics, second opinions, biomarker testing

🧬 Precision Oncology Centers

Impact: 100% reproducibility in HER2/PD-L1 scoring for treatment selection

Biomarker quantification, therapy eligibility, clinical trial enrollment

🧪 Pharmaceutical Companies

Impact: 60% faster clinical trial biomarker analysis

Central pathology review, biomarker endpoint assessment, trial enrollment screening

📊 Clinical Impact

🎯 98% Sensitivity

Cancer detection accuracy

⏱️ 50% Reduction

Pathologist screening time

📉 90% Fewer

Missed micrometastases

✅ 100% Reproducibility

Biomarker quantification consistency

🔬 OncosightAI